Nanotherapeutics and Nanotheragnostics for Cancers: Properties, Pharmacokinetics, Biopharmaceutics, and Biosafety.
Nanomedicine
advanced drug delivery
cancer drugdelivery
cancer nanotheragnostics
drug nanoparticles
nanosafety.
nanotheragnostics
nanotherapeutics
pharmacokinetics
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
02
2021
accepted:
24
06
2021
pubmed:
6
8
2021
medline:
29
3
2022
entrez:
5
8
2021
Statut:
ppublish
Résumé
With the increasing worldwide rate of chronic diseases, such as cancer, the development of novel techniques to improve the efficacy of therapeutic agents is highly demanded. Nanoparticles are especially well suited to encapsulate drugs and other therapeutic agents, bringing additional advantages, such as less frequent dosage requirements, reduced side effects due to specific targeting, and therefore increased patient compliance. However, with the increasing use of nanoparticles and their recent launch on the pharmaceutical market, it is important to achieve high-quality control of these advanced systems. In this review, we discuss the properties of different nanoparticles, the pharmacokinetics, the biosafety issues of concern, and conclude with novel nanotherapeutics and nanotheragnostics for cancer drug delivery.
Identifiants
pubmed: 34348617
pii: CPD-EPUB-117017
doi: 10.2174/1381612827666210804102645
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104-115Subventions
Organisme : FEDER
ID : UIDB/04469/2020
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.